Senti Biosciences, Inc. announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (?AML?). AML is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (?CAR-NK?) investigational cell therapy, is designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including AML, while sparing healthy bone marrow cells.

Initial efficacy data is anticipated by year-end 2024 and initial durability data following in 2025. The Phase 1 clinical trial of SENTI-202 (NCT06325748) is enrolling adult patients with relapsed or refractory (?r/r?) CD33 and/or FLT3 expressing hematologic malignancies, including AML, at multiple sites in the United States and Australia. The dose finding trial is evaluating two dose levels, either 1 or 1.5 billion SENTI-202 cells, administered in cycles, each comprising of three once-per-week doses, after disease specific lymphodepleting conditioning.

Patients may continue to receive multiple cycles of treatment based on safety and efficacy data.